Creo Medical (CREO.L) expects FY revenue growth of 50%-60% in line with guidance
H1 adjusted EBIT was GBP -4.9 million.
Sept. 9 million. The company said it remains confident of delivering FY revenue growth in line with existing guidance of 50% to 60%. It also said Q3-26 YTD revenue growth is expected to be approximately 50%.